Loading clinical trials...

COMPLETEDPHASE4

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each.

NCT00542880•AstraZeneca

View on ClinicalTrials.gov

Summary

This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Outpatient, female or male aged ≥40 years, diagnosis of COPD with symptoms for at least 2 years
•FEV1 ≤50% of predicted normal value, pre-bronchodilator, FEV1/VC \<70%
•Pre-bronchodilator

Exclusion Criteria

•Current respiratory tract disorder other than COPD
•History of asthma or rhinitis
•Significant or unstable cardiovascular disorder

Locations (59)

Research Site

Monte Grande, Buenos Aires, Argentina

Research Site

Quilmes, Buenos Aires, Argentina

Research Site

San Miguel de Tucumán, Tucumán Province, Argentina

Research Site

Ciudad Autonoma de Bs. As., Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Concord, New South Wales, Australia

Research Site

Adelaide, South Australia, Australia

Research Site

Daw Park, South Australia, Australia

Research Site

Woodville South, South Australia, Australia

Research Site

Melbourne, Victoria, Australia

Key Dates

Start Date

September 1, 2007

Primary Completion Date

August 1, 2008

Completion Date

August 1, 2008

Last Updated

August 30, 2012

Enrollment

442

ACTUAL participants

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg

DRUG

Seretide Diskus (salmeterol/fluticasone) 50/500 μg

DRUG

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease

NCT07382258

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGNA

Mindful-Breath for People With COPD

NCT07195838

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 30, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease

Mindful-Breath for People With COPD

The HELlenic Thoracic Society Initiative for CΟPD and CVD

Magnetic Stimulation of Diaphragm in Chronic Obstructive Pulmonary Disease

COPD Exacerbation Modelling Using Unobtrusive Sensors - the TOLIFE Clinical Study A